CRIS Current Research Information System

AUTERI, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.017
EU - Europa 825
AS - Asia 356
AF - Africa 72
SA - Sud America 3
OC - Oceania 2
Totale 2.275
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.010
IT - Italia 212
SE - Svezia 159
GB - Regno Unito 127
DE - Germania 124
VN - Vietnam 94
SG - Singapore 92
IN - India 88
IE - Irlanda 59
CN - Cina 45
TG - Togo 35
FR - Francia 30
RU - Federazione Russa 26
CI - Costa d'Avorio 21
FI - Finlandia 18
JO - Giordania 16
BG - Bulgaria 14
BE - Belgio 13
CH - Svizzera 11
NG - Nigeria 10
EE - Estonia 9
CA - Canada 7
HK - Hong Kong 6
ZA - Sudafrica 6
CZ - Repubblica Ceca 5
PL - Polonia 5
IR - Iran 4
TR - Turchia 4
UA - Ucraina 4
AT - Austria 2
BR - Brasile 2
ES - Italia 2
NL - Olanda 2
TW - Taiwan 2
AU - Australia 1
BD - Bangladesh 1
CL - Cile 1
GE - Georgia 1
HR - Croazia 1
HU - Ungheria 1
JP - Giappone 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
Totale 2.275
Salva come PNG Salva come JPEG
Città #
Chandler 197
Southend 110
Dong Ket 93
Ashburn 86
Singapore 80
Fairfield 69
Dublin 59
Princeton 52
Bologna 50
Lomé 35
Hyderabad 34
Houston 33
Milan 29
Wilmington 29
Woodbridge 29
Seattle 28
Redmond 26
Cambridge 23
Ann Arbor 22
Abidjan 21
Turin 21
Bremen 18
Santa Clara 17
Amman 16
Helsinki 16
Nanjing 16
New York 16
Berlin 14
Sofia 14
Westminster 14
Brussels 13
Los Angeles 12
Boydton 9
Monheim 9
Bern 8
Abeokuta 7
Des Moines 7
Perugia 7
Beijing 6
Medford 6
Modena 6
Saint Petersburg 6
Toronto 6
Brno 5
Casalecchio di Reno 5
Fremont 5
Munich 5
Norwalk 5
Falls Church 4
Florence 4
Hong Kong 4
Leawood 4
Migliarino 4
Mountain View 4
Olalla 4
Paris 4
Redwood City 4
Rome 4
San Diego 4
Shenyang 4
Andover 3
Bühl 3
Cernusco sul Naviglio 3
Changsha 3
Lagos 3
Limidi 3
Nanchang 3
Pune 3
San Francisco 3
Warsaw 3
Amsterdam 2
Bari 2
Central 2
Chicago 2
Fiesole 2
Forlì 2
Hefei 2
Hounslow 2
Imola 2
Kuban 2
Lappeenranta 2
Madrid 2
Mannheim 2
Monte di Procida 2
Parma 2
Poggio Renatico 2
Romainville 2
Shanghai 2
Taipei 2
Taizhou 2
Torino 2
Vienna 2
Zanjan 2
Zhengzhou 2
Abano Terme 1
Altoona 1
Auckland 1
Bagnacavallo 1
Boardman 1
Bonn 1
Totale 1.526
Salva come PNG Salva come JPEG
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 138
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 138
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 138
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 132
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 131
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 129
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 126
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 107
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 104
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 101
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 91
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 86
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 85
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 75
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. 71
null 68
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 59
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 59
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 57
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 57
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 56
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 52
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS-13 activity and autoantibodies 46
Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia 36
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 35
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 33
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 26
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 24
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 19
Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity 19
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 17
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with Myelofibrosis 16
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 16
Spleen and Liver Fibrosis Is Associated to Treatment Response and Prognosis in Philadelphia-Negative Chronic Myeloproliferative Neoplasms 11
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 10
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report 10
Predictors of Response to Hydroxyurea and Switch to Ruxolitinib in HU-Resistant Polycythaemia VERA Patients: A Real-World PV-NET Study 9
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 9
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study 7
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 5
Totale 2.408
Salva come PNG Salva come JPEG
Categoria #
all - tutte 8.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020188 0 0 0 13 22 19 25 38 27 21 17 6
2020/2021295 37 14 8 2 2 17 7 23 50 3 8 124
2021/2022546 8 17 24 51 32 22 11 49 19 53 155 105
2022/2023760 56 100 45 104 62 78 15 46 137 28 57 32
2023/2024316 16 49 23 32 20 45 2 30 13 30 31 25
2024/2025185 90 95 0 0 0 0 0 0 0 0 0 0
Totale 2.408